HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

Benzinga · 4d ago
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.